Stock Report

Download full stock data and analysis for free Last Updated: 27-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Emcure Pharmaceuticals Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: EMCURE | BSE: 544210

₹1,950.60

up-down-arrow ₹-1.50 (-0.08%)

As on 25-Sep-2026IST

Market cap

info icon

₹36,902 Cr

Revenue (TTM)

info icon

₹9,683 Cr

P/E Ratio

info icon

36.5

P/B Ratio

info icon

7.1

Div. Yield

info icon

0.2 %

Edit peer-selector-edit
Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Market cap (₹ Cr)
 36,902 28,103 16,761 15,213 13,199
Revenue (₹ Cr)
 9,683 2,372 2,590 1,108 676
Net Profit (₹ Cr)
 1,018.97 497.77 603.02 270.18 183.60
Net Margin (%)
 10.47 20.72 22.63 23.29 26.06
RoE (%)
 21.30 28.49 19.61 14.45 22.72
Price to Earnings
 36.49 56.46 27.79 55.25 72.27
Price-To-Book
 7.05 13.90 4.81 7.34 14.29

Income Statement (₹ Cr)

Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Operating Revenue arrow
9,683.45 2,371.81 2,590.40 1,108.39 675.61
Total Income arrow
9,730.84 2,402.61 2,664.23 1,159.90 704.48
Total Expenditure arrow
7,739.53 1,608.91 1,753.71 720.01 442.67
EBITDA arrow
1,943.92 762.90 836.69 388.38 232.94
Depreciation arrow
425.10 98.11 78.88 74.78 15.56
EBIT arrow
1,518.82 664.79 757.81 313.60 217.38
Interest arrow
148.45 26.33 5.43 0.26 7.96
Other Income arrow
47.39 30.80 73.83 51.50 28.87
Exceptional Items arrow
-27.85 0.00 -25.66 -3.28 0.00
Profit before Tax arrow
1,389.91 669.26 800.55 361.56 238.30
Provision for Tax arrow
370.94 171.48 197.53 91.39 54.69
Profit after Tax arrow
1,018.97 497.77 603.02 270.18 183.60

Liabilities (₹ Cr)

Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Shareholder's Funds arrow
4,950.03 1,874.47 3,332.13 2,017.06 883.34
Minority Interest arrow
-7.58 0.00 0.00 2.51 -0.97
Non-Current Liabilities arrow
723.57 345.47 142.73 50.51 74.82
Current Liabilities arrow
3,912.24 710.20 508.04 169.08 201.96
Total Liabilities arrow
9,514.48 2,930.14 4,157.10 2,231.79 1,174.38

Assets (₹ Cr)

Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Non-Current Assets arrow
3,392.16 1,290.62 1,321.38 957.22 477.92
Current Assets arrow
5,612.10 1,483.13 2,649.36 1,250.11 623.97
Total Assets arrow
9,514.48 2,930.14 4,157.10 2,231.79 1,174.38
Total Debt* arrow
1,204.08 196.61 0.00 0.00 148.29
Net Current Assets arrow
1,699.86 772.93 2,141.33 1,081.04 422.01
Contingent Liabilities arrow
258.92 13.18 4.82 3.76 --

Cashflow (₹ Cr)

Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Cash From Operating Activities arrow
943.55 346.68 565.41 266.88 69.55
Cash Flow from Investing Activities arrow
-1,193.06 -423.73 -570.15 -142.72 -330.93
Cash from Financing Activities arrow
343.43 20.98 -64.34 -112.88 247.29
Net Cash Inflow / Outflow arrow
93.92 -56.08 -69.08 11.28 -14.09

Ratios

Profitability Ratios

 Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
ROCE (%) arrow
25.25 27.50 24.61 18.04 28.50
ROE (%) arrow
21.30 28.49 19.61 14.45 22.72
ROA (%) arrow
11.42 19.48 16.31 12.66 31.25
EBIT Margin (%) arrow
15.68 28.03 29.25 28.29 32.18
Net Margin (%) arrow
10.47 20.72 22.63 23.29 26.06
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Revenue Growth (%) arrow
18.36 78.33 7.93 -6.72 23.56
EBIT Growth (%) arrow
30.43 303.07 19.88 -26.64 12.00
Net Profit Growth (%) arrow
32.39 182.61 21.66 -24.38 20.07
EPS Growth (%) arrow
36.68 277.72 25.42 -21.99 50.65
Book Value Growth (%) arrow
11.36 22.95 18.43 11.27 79.97

Valuation Ratios

 Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Price / Earnings arrow
35.74 56.46 26.91 54.76 69.46
Price / Book Value arrow
7.05 13.90 4.81 7.34 14.29
Dividend Yield (%) arrow
0.19 0.16 0.37 0.52 0.13
EV/EBITDA arrow
19.53 36.63 19.10 38.10 56.81
Market Cap (₹ Cr) arrow
30,257.56 15,412.11 11,956.86 10,627.92 6,690.53

Solvency Ratios

 Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Debt to Equity arrow
0.05 0.09 0.00 0.00 0.04
Short term debt to equity ratio arrow
0.16 -- -- -- 0.12
Current Ratio arrow
1.43 2.09 5.21 7.39 3.09
Quick Ratio arrow
0.82 1.37 3.85 5.46 2.02
Interest Coverage arrow
10.36 26.41 148.49 1,386.30 30.94

Operating Efficiency Ratios

 Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech Sudeep Pharma
Debtors to sales (%) arrow
26.46 22.82 41.42 41.52 33.68
Asset Turnover arrow
1.09 0.93 0.70 0.52 1.15
Receivable days arrow
88.68 77.32 144.58 169.86 115.16
Inventory Days arrow
84.11 80.83 96.67 97.92 96.15
Payable days arrow
176.65 125.94 135.45 159.68 106.08
Cash Conversion Cycle arrow
-3.86 32.22 105.80 108.11 105.23
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...